Multicentric Cohort of Melanoma Patients in Ile de France Area
NCT00839410 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1255
Last updated 2019-10-04
Summary
This is a multicentric prospective cohort of all stage melanoma patients from AP-HP ,the largest consortium of University hospitals over Europe. 7 investigation sites (7 dermatological services of AP-HP) in Ile de France region are involved. 1300 patients will be enrolled and be followed during 10 years.
Conditions
- Melanoma
- Genetic Polymorphism
Sponsors & Collaborators
-
Assistance Publique - Hôpitaux de Paris
lead OTHER
Principal Investigators
-
Philippe Saiag, MD · Assistance Publique - Hôpitaux de Paris
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2003-09-30
- Primary Completion
- 2019-10-31
- Completion
- 2019-10-31
Countries
- France
Study Locations
More Related Trials
-
Study of Alterations in Tumor Metabolism Associated With the Development of Immunotherapy Resistance in Melanoma
NCT05307289 ·Status: RECRUITING ·Phase: NA
-
One-year Recurrence-free Survival of Melanoma Patients Eligible for a Sentinel Lymph Node Biopsy
NCT06809491 ·Status: ACTIVE_NOT_RECRUITING
-
Characterisation of T Lymphocytes, NK Cells and Macrophages in Melanoma Patients
NCT01336270 ·Status: COMPLETED
-
Follow-up of a National Cohort of Melanoma Resectable Stage II, Stage III or IV Patients or Unresectable Primary
NCT02828202 ·Status: RECRUITING
-
Study of Molecular Mechanisms Implicated in the Pathogenesis of Melanoma. Role of Exosomes
NCT02310451 ·Status: COMPLETED ·Phase: NA
-
An Analysis of Treatment Patterns and Outcomes for Basal Cell Carcinoma (BCC) Cancer Participants
NCT02100111 ·Status: COMPLETED
-
Itch and Pain Characteristics in Skin Carcinomas
NCT03290989 ·Status: COMPLETED
-
Study of Risk Factors and Clinical Characterization of Rapidly Growing Melanoma
NCT02879474 ·Status: UNKNOWN
-
Generation of an Artificial Intelligence Algorithm Based on the Analysis of Melanoma Peri-scar Dermatoheliosis, as a Predictive Factor of Response to Anti-PD-1
NCT05856565 ·Status: RECRUITING
-
Pre Transplantation Melanoma
NCT04217382 ·Status: COMPLETED
-
Spanish Academy of Dermatology and Venereology (AEDV) Melanoma Registry
NCT05673681 ·Status: RECRUITING
-
An Observational Study of BRAF Inhibitors Effectiveness in Patients With Newly Diagnosed Metastatic Melanoma
NCT02143999 ·Status: COMPLETED
-
RCT Treatment Versus Non Treatment of Low-risk BCCs in Elderly
NCT05110924 ·Status: TERMINATED ·Phase: NA
-
Expression of IL4 Induced Gene 1 in Patients With Cutaneous Melanoma: Value in Prognosis and/or in Predictive Response to Immune Checkpoint Inhibitors
NCT04253080 ·Status: COMPLETED ·Phase: NA
-
Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of Melanoma
NCT00040352 ·Status: RECRUITING
-
Effectiveness, Safety and Use of Nivolumab Administered During the French Temporary Authorization for Use in Patients With Advanced Melanoma
NCT03504696 ·Status: COMPLETED
-
Identification and Characterization of Circulating Tumor Cells Before and After Treatment (Surgery and Radiotherapy) in a Cohort of Patients Treated for Resectable Stage I-III Merkel Cell Carcinoma
NCT06448611 ·Status: NOT_YET_RECRUITING
-
A Study of APR-246 in Combination With Dabrafenib in Resistant Patients With BRAF V600 Mutant Melanoma
NCT03391050 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Treatment Patterns and Outcomes Study in Patients With Unresectable Stage III and Metastatic (Stage IV) Melanoma in the United States
NCT03199846 ·Status: COMPLETED
-
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
NCT01511913 ·Status: COMPLETED
-
Real-life Pharmacological Monitoring of Encorafenib-Binimetinib in the Treatment of Metastatic Melanoma
NCT06774989 ·Status: RECRUITING
-
Profiling of Circulating Immune Cells to Uncover Response Signatures to Anti-PD1 Immunotherapy in Melanoma Patients
NCT06154668 ·Status: RECRUITING
-
Vemurafenib and Cobimetinib Combination in BRAF Mutated Melanoma With Brain Metastasis
NCT02537600 ·Status: COMPLETED ·Phase: PHASE2
-
French Clinical Datbase of Melanoma Patients (RIC-Mel)
NCT03315468 ·Status: RECRUITING
-
Characterization of NK Cells Under First Line Advanced Therapy Either as Curative Therapy for Metastatic Melanoma or as Adjuvant Therapy for High-risk of Recurrence
NCT05062096 ·Status: UNKNOWN ·Phase: NA